1 – 10 of 426
- show: 10
- |
- sort: year (new to old)
- |
- Export
- 2024
- PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial (2024) EUROPEAN UROLOGY ONCOLOGY. 7(3). p.462-468
- Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy : real-world data from the E2-RADIatE OligoCare cohort (2024) CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 45.
- Nonpharmacological interventions for managing the dyspnea-fatigue-physical/role functioning symptom cluster in lung cancer patients : a systematic review (2024) EUROPEAN JOURNAL OF CANCER CARE. 2024. p.1-24
- Moderate hypofractionated radiotherapy for prostate cancer : 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial (2024) RADIOTHERAPY AND ONCOLOGY. 193.
- Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer : a qualitative study exploring patient priorities and counselling needs when making a treatment choice (2024) BMC CANCER. 24(1).
- Androgen deprivation therapy in advanced prostate cancer : insights from a real-world patient survey on health-related quality of life and information and communication sources (2024) QUALITY OF LIFE RESEARCH.
- PI-RADS 5 in prostate magnetic resonance imaging : how important is intraprostatic invasive behavior? (2024) European Congress of Radiology 2024 (ECR 2024), Abstracts.
- Incidence and radiotherapy treatment patterns of complicated bone metastases (2024) JOURNAL OF BONE ONCOLOGY. 44.
- Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease : an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study (2024) RADIOTHERAPY AND ONCOLOGY. 195.
- Docetaxel provides oncological benefits in the era of new-generation androgen receptor inhibitors : or is three a crowd? (2024) CLINICAL GENITOURINARY CANCER. 22(1). p.56-66